Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz
Key Highlights
- ➤MitoCareX completes initial AI-powered computational screening with Boltz
- ➤Preliminary predictions warrant further analysis and experimental validation
- ➤Computational findings remain unvalidated and may not yield viable candidates
- ➤MitoCareX retains control over discovery programs and advanced candidates
MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation
Ness Ziona, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) recently announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has completed an initial computational screening stage under its drug-discovery initiative with Boltz, PBC (“Boltz”), an AI research lab focused on biomolecular foundation models and drug-discovery workflows. MitoCareX believes the preliminary computational predictions generated in this stage are encouraging and warrant further computational analysis and experimental validation.
Get started
Create a free account to read the full story.